A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

751

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Breast Cancer
Interventions
DRUG

Docetaxel

Docetaxel monotherapy: docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle. DOXIL in combination with docetaxel: docetaxel 60 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle

DRUG

DOXIL

DOXIL 30 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.

Trial Locations (147)

Unknown

Hoover

Fountain Valley

Long Beach

Los Angeles

Palm Springs

Newark

Lakeland

Fort Gordon

Centralia

Joliet

Indianapolis

Lexington

Louisville

Lafayette

Baltimore

Jackson

Las Vegas

Newark

Albuquerque

Cooperstown

New York

The Bronx

Gastonia

Philadelphia

Upland

Providence

Charleston

North Charleston

Fort Worth

Pasadena

Plovdiv

Shumen

Sofia

Stara Zagora

Varna

Tartu

Rabat-les-Trois-Seigneurs

Tunis

Budapest

Debrecen

Szeged

Székesfehérvár

Zalaegerszeg

Ashkelon

Haifa

Jerusalem

Ramat Gan

Tel Aviv

Riga

Kaunas

Vilnius

Arnhem

Capelle aan den IJssel

Roosendaal

The Hague

Bialystok

Bydgoszcz

Bytom

Gdansk

Gdynia

Gliwice

Kielce

Koszalin

Krakow

Lodz

Lublin

Olsztyn

Poznan

Warsaw

Coimbra

Matosinhos Municipality

Bacau

Bucharest

Cluj-Napoca

Hunedoara

Iași

Onești

Timișoara

Arkhangelsk

Balashikha

Barnaul

Chelyabinsk

Engels Saratov Region

Irkutsk

Ivanovo

Izhevsk

Kazan'

Krasnodar

Leningrad Region

Lipetsk

Moscow

Moscow Region

Murmansk

Nizhny Novgorod

Novosibirsk

Obninsk

Omsk

Oryol

Petrozavodsk

Pyatigorsk

Rostov-on-Don

Ryazan

Saint Petersburg

Samara

Smolensk

Stavropol

Tomsk

Tver'

Ulyanovsk

Vladimir

Volgograd

Voronezh

Yaroslavl

Yekaterinburg

Belgrade

Kamenitz

Niš

Cape Town

Johannesburg

Kimberley

Parktown

Port Elizabeth

Pretoria

Pretoria Gauteng

Bilbao Vizcaya

Lleida

Madrid

Santander

Seville

Cherkassy

Chernivtsi

Dnipro

Donetsk

Kharkiv

Kiev

Luhansk

Lutsk

Odesa

Poltava

Simferopol

Uzhhorod

Vinnitsa

Zhytomyr

Huddersfield

Manchester

Nottingham

Sutton

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00091442 - A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer | Biotech Hunter | Biotech Hunter